A pivotal year for NAFLD and NASH therapeutics
Nat Rev Endocrinol
.
2024 Feb;20(2):75-76.
doi: 10.1038/s41574-023-00939-9.
Author
Jean-François Dufour
1
Affiliation
1
Center for Digestive Diseases Lausanne, Lausanne, Switzerland. Jf.dufour@svmed.ch.
PMID:
38097670
DOI:
10.1038/s41574-023-00939-9
No abstract available
MeSH terms
Humans
Liver
Non-alcoholic Fatty Liver Disease* / drug therapy
Risk Factors